 |
|
|
| |
Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and treatment-naïve chronic hepatitis B patients: 48-week treatment and post treatment follow up
|
| |
| |
EASL 2022 June 22-26 London
Man-Fung YUEN1, Rozalina BALABANSKA2, Jinlin HOU3, Edward J GANE4, Tien Huey LIM5, Wenhong ZHANG6, Qing XIE7, Piyawat KOMOLMIT8, Apinya LEERAPUN9, Sheng-Shun
YANG10, Chau-Ting YEH11, Wen ZHANG12, Xue ZHOU12, Zenghui XUE13, Miriam TRIYATNI14, Ethan CHEN13, Rui LI12, Qingyan BO13
1Queen Mary Hospital, The University of Hong Kong, Hong Kong, China; 2Acibadem City Clinic Tokuda Hospital EAD, Sofia, Bulgaria; 3Nanfang Hospital, Southern Medical University, Guangzhou, China; 4New Zealand Liver Transplant Unit, The University of Auckland, Auckland, New Zealand; 5Middlemore Hospital, Auckland, New Zealand; 6Huashan Hospital, Fudan University, Shanghai, China; 7Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; 8King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 9Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand; 10Taichung Veterans General Hospital, Taichung, Taiwan; 11Chang Gung Memorial Hospital, Linkou Branch,Taoyuan, Taiwan; 12Roche Pharma Research and Early Development, Roche Innovation Centre Shanghai, Shanghai, China; 13Roche (China) Holding, Shanghai, China; 14F. Hoffmann-La Roche, Basel, Switzerland.
|
| |
|
|
|
|
|
